Long Ideas - Since pricing its latest public offering at $5.50 two weeks ago, shares of Synergy Pharmaceuticals (SGYP) have failed to hold that print and are trading … Continue Reading
Read NowLong Ideas - ICPT has a big problem, and could be headed back to its post-IPO prices, 50% lower than where they trade today. The company piqued our … Continue Reading
Read NowMost Popular - Exact Sciences (EXAS) on Thursday released the long-awaited results of its DeeP-C trial examining the use of its Cologuard test in the detection of CRC … Continue Reading
Read NowMost Popular - Intercept Pharmaceuticals’ (ICPT) shares immediately took off from their late October IPO price of $15 per share, soaring to a closing high of $41.70 on … Continue Reading
Read NowInterviews - On April 11, PropThink hosted an Interview and Q&A (via conference call) for PropThink subscribers with Dr. Scott Chambers, a leading patent attorney and former … Continue Reading
Read NowMost Popular - Keryx (KERX) has come back under the magnifying glass at PropThink. We hosted Dr. Scott Chambers, a patent attorney and former USPTO staff, on a … Continue Reading
Read NowLong Ideas - Following PropThink’s conference call with Dr. Scott Chambers on Thursday, we’re quite comfortable with the short-term and long-term patent protection on Zerenex, Keryx’s (KERX) novel … Continue Reading
Read Now
